The PSMA paradox: How biology, androgen signaling, and therapy sequencing shape Lu-177 efficacy

Current Radiopharmaceuticals · Published 2026-07-01 · DOI 10.1016/j.craph.2026.100069

Free full text

Authors (1)

Arif Hakan Önder

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Önder, A. (2026). The PSMA paradox: How biology, androgen signaling, and therapy sequencing shape Lu-177 efficacy. Current Radiopharmaceuticals. https://doi.org/10.1016/j.craph.2026.100069

Related articles

• RNA Binding Proteins are Pivotal Regulators of Cancer Radioresistance and Potential Targets for Preventing Tumor Recurrence · Current Radiopharmaceuticals · 2025 · Same journal
• Analysis of set-up errors in daily kilovolt fan beam CT for rectal cancer treated with volumetric modulated arc therapy · Current Radiopharmaceuticals · 2025 · Same journal
• Anatomy as a guide: Using learned priors for precise organ segmentation · Current Radiopharmaceuticals · 2026 · Same journal
• Comparative dosimetric analysis of hippocampal-sparing vs conventional craniospinal irradiation in central nervous system leukemia: A single-center study · Current Radiopharmaceuticals · 2025 · Same journal
• EAVS-TF: A bio-inspired spiking neural network for energy-efficient multimodal emotion recognition · Current Radiopharmaceuticals · 2026 · Same journal
• Preclinical Aspects of [89Zr]Zr-DFO-Rituximab: A High Potential Agent for Immuno-PET Imaging · Current Radiopharmaceuticals · 2024 · Same journal
• Radioprotective effects of curcumin during radiotherapy: Critical evaluation of preclinical and clinical evidence · Current Radiopharmaceuticals · 2026 · Same journal
• Enhancing Ketoprofen Solubility: A Strategic Approach Using Solid Dispersion and Response Surface Methodology · Current Radiopharmaceuticals · 2024 · Same journal
• An Analysis of the Radiosensitiser Applications in the Biomedical Field · Current Radiopharmaceuticals · 2024 · Same journal
• The role of 131I in the treatment and management of thyroid cancer · Current Radiopharmaceuticals · 2025 · Same journal